Logo

Margot Schoenborn

Jun 26, 2019

OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO. Schoenborn joined the firm as senior VP, general counsel and corporate secretary in 2015 and was later appointed chief administrative officer. Prior to OmniSeq, Schoenborn served as deputy general counsel at the Roswell Park Comprehensive Cancer Center. Before that, she served as a special assistant attorney general for New York and as a assistant US attorney for the Eastern District of New York. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.